BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...Lou ReeseUniversity collaborators: University of Nebraska Medical Center, University of Southampton...
BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

...days for placebo (HR=1.72, 95% CI: 0.91, 3.25; p=0.096). IFNB1 for COVID-19 Synairgen co-founder and University of Southampton...
BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

...alone could not do. Carbohydrate binding sites mapped onto SARS-CoV-2 spike protein Researchers at the University of Southampton...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

...Founded: 2016 by Syncona Ltd. University: University of Cambridge, University of Newcastle, University of Oxford, University of Southampton...
BioCentury | Oct 26, 2018
Financial News

Stoke prepares for IND, IPO with $90M series B

...Augmentation of Nuclear Gene Output (TANGO) platform, in-licensed from Cold Spring Harbor Laboratory and the University of Southampton...
BioCentury | Oct 23, 2018
Financial News

Stoke prepares for IND, IPO with $90M series B

...Augmentation of Nuclear Gene Output (TANGO) platform, in-licensed from Cold Spring Harbor Laboratory and the University of Southampton...
BioCentury | Apr 5, 2018
Emerging Company Profile

Stoking protein production

...head of biology. Stoke has exclusively licensed the TANGO IP from Cold Spring and the University of Southampton...
...status: Preclinical Founded: 2014 by Adrian Krainer, Isabel Aznarez University collaborators: Cold Spring Harbor Laboratory, University of Southampton...
...New York, N.Y. Stoke Therapeutics Inc., Bedford, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan University of Southampton...
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

...ADAMTSL1) Two SNPs on ADAMTSL1 could help predict disease-free survival in early-onset breast cancer patients. University of Southampton...
BioCentury | Jan 12, 2018
Translation in Brief

In the twenties

...A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists...
...direct tumor-targeting antibodies.” Lim is an associate professor and honorary consultant in hematological oncology at University of Southampton...
...tumors. “It opens the door to examining anti-CD27 in other direct tumor-targeting combinations.” Sean Lim, University of Southampton...
BioCentury | Jan 2, 2018
Distillery Techniques

Biomarkers

...21, 2017 doi:10.1038/s41467-017-01775-y CONTACT: William Tapper, University of Southampton, Southampton General Hospital, Southampton, U.K. email: W.J.Tapper@soton.ac.uk Karen Tkach Tuzman University of Southampton ADAMTS...
Items per page:
1 - 10 of 39
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...Lou ReeseUniversity collaborators: University of Nebraska Medical Center, University of Southampton...
BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

...days for placebo (HR=1.72, 95% CI: 0.91, 3.25; p=0.096). IFNB1 for COVID-19 Synairgen co-founder and University of Southampton...
BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

...alone could not do. Carbohydrate binding sites mapped onto SARS-CoV-2 spike protein Researchers at the University of Southampton...
BioCentury | Feb 22, 2019
Emerging Company Profile

Gyroscope complements dry AMD

...Founded: 2016 by Syncona Ltd. University: University of Cambridge, University of Newcastle, University of Oxford, University of Southampton...
BioCentury | Oct 26, 2018
Financial News

Stoke prepares for IND, IPO with $90M series B

...Augmentation of Nuclear Gene Output (TANGO) platform, in-licensed from Cold Spring Harbor Laboratory and the University of Southampton...
BioCentury | Oct 23, 2018
Financial News

Stoke prepares for IND, IPO with $90M series B

...Augmentation of Nuclear Gene Output (TANGO) platform, in-licensed from Cold Spring Harbor Laboratory and the University of Southampton...
BioCentury | Apr 5, 2018
Emerging Company Profile

Stoking protein production

...head of biology. Stoke has exclusively licensed the TANGO IP from Cold Spring and the University of Southampton...
...status: Preclinical Founded: 2014 by Adrian Krainer, Isabel Aznarez University collaborators: Cold Spring Harbor Laboratory, University of Southampton...
...New York, N.Y. Stoke Therapeutics Inc., Bedford, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan University of Southampton...
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

...ADAMTSL1) Two SNPs on ADAMTSL1 could help predict disease-free survival in early-onset breast cancer patients. University of Southampton...
BioCentury | Jan 12, 2018
Translation in Brief

In the twenties

...A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists...
...direct tumor-targeting antibodies.” Lim is an associate professor and honorary consultant in hematological oncology at University of Southampton...
...tumors. “It opens the door to examining anti-CD27 in other direct tumor-targeting combinations.” Sean Lim, University of Southampton...
BioCentury | Jan 2, 2018
Distillery Techniques

Biomarkers

...21, 2017 doi:10.1038/s41467-017-01775-y CONTACT: William Tapper, University of Southampton, Southampton General Hospital, Southampton, U.K. email: W.J.Tapper@soton.ac.uk Karen Tkach Tuzman University of Southampton ADAMTS...
Items per page:
1 - 10 of 39